<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01893528</url>
  </required_header>
  <id_info>
    <org_study_id>R2009-HV-1304</org_study_id>
    <nct_id>NCT01893528</nct_id>
  </id_info>
  <brief_title>Study to Assess the Safety and Tolerability of Ascending Single Doses of REGN2009 in Healthy Volunteers</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1, randomized, double-blind, placebo-controlled first-in-human (FIH) study to
      assess the safety and tolerability of ascending single doses of REGN2009 administered to
      healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of TEAEs</measure>
    <time_frame>day 1 to day 106/ visit 15</time_frame>
    <description>The primary endpoint in this study is the incidence and severity of Treatment Emergent Adverse Events (TEAEs) in healthy volunteers treated with REGN2009 or placebo reported from day 1 (baseline) to the completion of the study on day 106/ visit 15.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>REGN2009 dose level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort A - REGN2009 or placebo; Cohort B - Patients on existing (non-exclusionary) medications + (REGN2009 or placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>REGN2009 dose level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort C - REGN2009 or placebo; Cohort D - Patients on existing (non-exclusionary) medications + (REGN2009 or placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>REGN2009 dose level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort E - REGN2009 or placebo; Cohort F - Patients on existing (non-exclusionary) medications + (REGN2009 or placebo)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>REGN2009</intervention_name>
    <arm_group_label>REGN2009 dose level 1</arm_group_label>
    <arm_group_label>REGN2009 dose level 2</arm_group_label>
    <arm_group_label>REGN2009 dose level 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>REGN2009 dose level 1</arm_group_label>
    <arm_group_label>REGN2009 dose level 2</arm_group_label>
    <arm_group_label>REGN2009 dose level 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy men and women ages 18 to 65 years inclusive

          2. Body mass index between 18.0 kg/m^2 and 30.0 kg/m^2, inclusive

        Exclusion Criteria:

          1. Pregnant or breast-feeding women

          2. Any clinically significant abnormalities observed during screening (day -21 to day -2)

          3. Known history of human immunodeficiency virus (HIV) antibody; and/or positive
             hepatitis B surface antigen, and/or positive hepatitis C antibody at the screening
             visit

          4. History of drug or alcohol abuse within a year prior to the screening visit (day -21
             to day -2)

          5. Hospitalization for any reason within 60 days of the screening visit (day -21 to day
             -2)

          6. Participation in any clinical research study within 30 days of the screening visit
             (day -21 to day -2) or within 5 half-lives of the investigational drug or therapy
             being studied (whichever is longer)

          7. History of a hypersensitivity reaction to doxycycline or similar compound

          8. Any medical or psychiatric condition which, in the opinion of the investigator, would
             place the subject at risk, interfere with participation in the study or interfere with
             the interpretation of the study results

          9. Previous adverse experience to any biological investigational or therapeutic agent

         10. Sexually active men or women of childbearing potential who are unwilling to practice
             adequate contraception during the study

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial and not all inclusion/ exclusion criteria are
        listed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2013</study_first_submitted>
  <study_first_submitted_qc>July 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2013</study_first_posted>
  <last_update_submitted>November 7, 2014</last_update_submitted>
  <last_update_submitted_qc>November 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

